- Home
- CHRS vs SKYE Comparison
CHRS vs SKYE Comparison
Compare CHRS & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- SKYE
- Stock Information
- Founded
- CHRS 2010
- SKYE 2012
- Country
- CHRS United States
- SKYE United States
- Employees
- CHRS N/A
- SKYE N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- SKYE Health Care
- Exchange
- CHRS Nasdaq
- SKYE Nasdaq
- Market Cap
- CHRS 102.0M
- SKYE 101.3M
- IPO Year
- CHRS 2014
- SKYE N/A
- Fundamental
- Price
- CHRS $1.05
- SKYE $3.51
- Analyst Decision
- CHRS Buy
- SKYE Buy
- Analyst Count
- CHRS 3
- SKYE 7
- Target Price
- CHRS $4.68
- SKYE $15.50
- AVG Volume (30 Days)
- CHRS 1.5M
- SKYE 353.1K
- Earning Date
- CHRS 08-07-2025
- SKYE 08-07-2025
- Dividend Yield
- CHRS N/A
- SKYE N/A
- EPS Growth
- CHRS N/A
- SKYE N/A
- EPS
- CHRS 1.55
- SKYE N/A
- Revenue
- CHRS $272,209,000.00
- SKYE N/A
- Revenue This Year
- CHRS N/A
- SKYE N/A
- Revenue Next Year
- CHRS $142.61
- SKYE N/A
- P/E Ratio
- CHRS $2.05
- SKYE N/A
- Revenue Growth
- CHRS 52.33
- SKYE N/A
- 52 Week Low
- CHRS $0.66
- SKYE $1.14
- 52 Week High
- CHRS $2.43
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- CHRS 62.88
- SKYE 49.12
- Support Level
- CHRS $0.81
- SKYE $2.96
- Resistance Level
- CHRS $0.95
- SKYE $3.71
- Average True Range (ATR)
- CHRS 0.07
- SKYE 0.31
- MACD
- CHRS 0.01
- SKYE -0.06
- Stochastic Oscillator
- CHRS 85.71
- SKYE 49.59
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.